Inclisiran prescribed to 7% of expected target population in three years, NHS data reveal
Fewer than 20,000 people in England have been prescribed anticholesterol drug inclisiran (Leqvio; Novartis) in primary care since 2021, despite expectations set by the NHS that 300,000 people would be taking the drug by 2024. A freedom of information request sent by The Pharmaceutical Journal to the NHS Business Services Authority (NHS BSA), revealed that 19,416 […]
Continue reading this article about Inclisiran prescribed to 7% of expected target population in three years, NHS data reveal
by Sheralyn Bone
NHS Forums - For daily discussion by NHS Staff.